~~<i id='9AE4460C8B'><strike id='9AE4460C8B'><tt id='9AE4460C8B'><pre id='9AE4460C8B'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

Wikipedia

fashion

author：leisure time 2025-08-29 19:54:46 - browse：8755

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Thermo Fisher plant for manufacturing gene therapies to expand

knowledge

entertainment

focus

knowledge

hotspot

AdobeThiswassupposedtobetheyearofthebiotechcomeback,whenpromisingnewmedicinesandhigh-dollarbuyoutswo

WSS

Leqembi, other new Alzheimer’s drugs require better biomarkers

Elizabeth Holmes on track for early release from her 11

What Congress can do to address the rural doctor shortage

Hearing on Medicare drug price negotiation gets unusually heated

Elizabeth Holmes on track for early release from her 11

California’s proposed $25 per hour health care minimum wage

Wikipedia

fashion

knowledge

Heart attack and stroke risk calculators need revising

Second xenotransplant done with gene

Wildfire smoke exposes gaps in outdoor worker protections

NIH fellows want a pay raise. Will that mean less money for grants?

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Intarcia’s device

In Memoriam: Notable people who died in 2023

Insurance companies sue energy corporation after it was blamed for helping start Colorado wildfire

Drug repurposing or repositioning? The language matters

Senators: Long

entertainment

Biden launches a new push to limit health care costs

It's time to get medical device identifiers over the finish line

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

Senate HELP committee spars over health care workforce policies

DOJ reversal could clear way for Carroll's 1st lawsuit against Trump to proceed

Palantir health business leans on meeting customers’ needs

focus

knowledge

knowledge

hotspot